Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Cutaneous T-Cell Lymphomas

April 27, 2021

Diagnosis and Management of Mycosis Fungoides and Sezary Syndrome
A multidisciplinary team approach involving hematology/oncology, dermatology, and radiation oncology is optimal for the management of patients with MF and SS, particularly those with advanced disease. Expert hematopathology review is needed to establish the histologic evidence of folliculartrophic mycosis fungoides (FMF) or large cell transformation (LCT) as well as to distinguish MF from benign inflammatory skin diseases. The optimal treatment should be individualized based on overall goals of therapy (attain adequate response in order to reduce and control symptoms as well as minimize the risk of progression), route of administration and toxicity profile of the therapeutic agent. Most of the treatment options do not result in durable remissions; therefore, therapies with lower side-effect profiles and an absence of cumulative toxicity are often given in an ongoing or maintenance fashion to maintain disease control and quality of life. Supportive care to minimize the risk of skin infections and treat pruritus is an important part of disease and symptom control. Given the rarity of the disease and the need for an individualized approach, it is preferred that patients receive treatment at specialized centers with expertise in the management of cutaneous T cell lymphomas (CTCL). Informing clinicians about the recommendations outlined in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Primary Cutaneous Lymphomas for the diagnosis and treatment of MF and SS can help them to develop an individualized treatment plan to improve quality of life and clinical outcomes.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the rationale behind the decision-making process in the diagnosis and management of mycosis fungoides (MF) and Sezary Syndrome (SS).
  • Review the evidence from clinical trials supporting the use of novel systemic biologic therapies for mycosis fungoides (MF) and Sezary Syndrome (SS). 
  • Develop an individualized treatment plan integrating recommendations outlined in the (NCCN Guidelines®) Primary Cutaneous Lymphomas for the management of mycosis fungoides (MF) and Sezary Syndrome (SS). 
Additional information

This activity is supported by educational grants from:

  • AstraZeneca
  • Clovis Oncology, Inc.
  • Daiichi Sankyo, Inc.
  • GlaxoSmithKline
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Seattle Genetics, Inc.
  • Taiho Oncology, Inc.

This activity is supported by independent educational grants from:

  • Astellas and Pfizer, Inc.
  • Merck  & Co., Inc.

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Sanofi Genzyme

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
Course expires: 
Event starts: 
04/27/2021 - 1:00pm EDT
Event ends: 
04/27/2021 - 2:00pm EDT

Neha Mehta-Shah, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Jennifer Pavlisin, NP
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses no relevant financial relationships: 
Jennifer Pavlisin, MSN, AGPCNP-BC

The faculty listed below discloses the following relevant financial relationships: 
Neha Mehta-Shah, MD
Bristol-Myers Squibb Company: Grant/Research Support
C4 Therapeutics: Consulting Fee
Celgene Corporation: Grant/Research Support
Corvus Pharmaceuticals: Grant/Research Support
Daiichi-Sankyo Co.: Consulting Fee
Genentech, Inc.: Grant/Research Support
Innate Pharmaceuticals: Grant/Research Support
Karyopharm Therapeutics: Consulting Fee
Kyowa Hakko Kirin Co., Ltd.: Consulting Fee
Ono Pharmaceuticals: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support
Secura Bio: Consulting Fee
Verastem Pharmaceuticals: Grant/Research Support

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Hema Sundar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-073-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00045976; Approval #: 210001344

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation


Please login or register to take this course.

This webinar was presented live one time only on Tuesday, April 27, 2021, from 1:00 – 2:00 PM EDT (UTC -4).  A recording will be available in approximately 1 week.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing